Today: 9 februari 2026
Subscribe
Search result

Phantom 4 RTK/feed/category/dji-mavic-3t-pl- Page 133

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer shares fell 3.4% to $25.77 in Wednesday’s premarket after Novo Nordisk warned of lower 2026 sales and price pressure in obesity drugs. Pfizer’s GLP-1 trial met its main goal, showing up to 12.3% mean weight loss at 28 weeks, but safety questions remain. The company reaffirmed 2026 guidance and reported $17.6 billion in Q4 revenue. Investors await more VESPER-3 data at the June 6 ADA meeting.
4 februari 2026
··
Constellation Software hits a 1-year low — why analysts still see upside in CSU

Constellation Software hits a 1-year low — why analysts still see upside in CSU

Constellation Software shares hovered near a 52-week low Wednesday on the Toronto Stock Exchange, trading around C$2,342 after a steep two-day drop. Several banks cut price targets, but analysts tracked by MarketBeat kept a “moderate buy” consensus. The Sequoia Fund called the valuation “compelling” in a shareholder letter. Leadership changes continue after founder Mark Leonard stepped down last September.
4 februari 2026
·
Reynolds Consumer Products stock jumps nearly 15% after Q4 results, steady 2026 outlook

Reynolds Consumer Products stock jumps nearly 15% after Q4 results, steady 2026 outlook

Reynolds Consumer Products shares jumped 14.6% to $25.00 after its Q4 earnings and 2026 outlook. The company reported Q4 net revenues of $1.034 billion and projected 2026 adjusted EBITDA of $660–$675 million, with EPS of $1.57–$1.63. The board approved a $0.23 dividend, payable Feb. 27. Retail revenues slipped, but non-retail sales rose sharply on higher aluminum demand.
4 februari 2026
··
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer shares rose 3.9% to $26.78 before holding steady after hours, following new data on its obesity drug PF-3944 and quarterly results. The company maintained its 2026 revenue and earnings outlook but warned of pricing pressures and upcoming patent expirations. Mid-stage trial data showed up to 12.3% weight loss at 28 weeks, with some patients dropping out due to side effects. Trading volume topped 80 million shares.
5 februari 2026
·
Cardinal Health stock jumps 9% after earnings beat — what CAH investors watch next

Cardinal Health stock jumps 9% after earnings beat — what CAH investors watch next

Cardinal Health shares jumped 9% to $226.05 Thursday after the company raised its fiscal 2026 adjusted earnings forecast to $10.15-$10.35 per share. Quarterly revenue rose 19% and adjusted profit beat estimates, driven by strong specialty drug demand. CEO Jason Hollar cited double-digit profit growth across all segments. Specialty medicines, including GLP-1 drugs, contributed significantly to revenue gains.
5 februari 2026
····
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 februari 2026
···
Tesla stock slides as Volkswagen tops Europe EV sales — what investors are watching next

Tesla stock slides as Volkswagen tops Europe EV sales — what investors are watching next

Tesla shares fell 2.7% to $394.85 after new data showed Volkswagen overtook Tesla in 2025 European battery-electric vehicle sales. January UK sales for Tesla plunged 57% year-on-year, while BYD and Ford gained ground. In China, Tesla’s market share slipped to 8% in 2025. A California judge signaled Tesla and CEO Elon Musk likely won’t get a copyright lawsuit dismissed.
5 februari 2026
···
Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook

Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook

Coloplast A/S shares fell 7.82% to 495.35 crowns in Copenhagen after the company slashed its Kerecis growth forecast to 10% due to new U.S. Medicare reimbursement rules. Group revenue for the quarter was flat at 7,043 million crowns, with EBIT before special items down 3% to 1,850 million. Coloplast will phase out Kerecis Shield in Medicare outpatient care and shift focus to its MariGen range.
6 februari 2026
·
Bitcoin 2026 Price Forecast: Futures Market Sees Only a Small Premium After $60,000 Test

Bitcoin 2026 Price Forecast: Futures Market Sees Only a Small Premium After $60,000 Test

Bitcoin rebounded above $65,000 Friday after dipping near $60,000, but remains down nearly 14% for the week, its steepest drop since November 2022. The CME December 2026 bitcoin futures contract hovered around $67,285, showing limited premium. U.S. spot bitcoin ETFs saw over $3 billion in outflows in January. BlackRock’s iShares Bitcoin Trust fell more than 13% Thursday.
6 februari 2026
···
Adobe stock slides as AI “software-mageddon” drags on — what investors watch next

Adobe stock slides as AI “software-mageddon” drags on — what investors watch next

Adobe shares fell 1.1% to $266.51 in Friday afternoon trading, lagging a broader market rebound. A Vanguard filing disclosed a 10.1% stake in the company as of Jan. 30. Adobe reversed plans to discontinue its Animate app, keeping it in maintenance mode. Investors await Adobe’s March 12 earnings call for updates on AI-driven revenue.
6 februari 2026
···
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 11:59 PM EST ASX set for relief rally as investors brace for volatile earnings season February 7, 2026, 11:24 PM EST. Australian shares are expected to rebound strongly on Monday, with S&P/ASX 200 futures up 1.2% after a sharp 2% drop on Friday, the worst since last April. Investors are preparing for a volatile earnings season as major companies including CSL, Commonwealth Bank, and James Hardie release results. The bounce reflects buyers stepping in after recent losses, but market swings may persist amid uncertainty surrounding blue-chip earnings performance.
7 februari 2026
1 … 131 132 133 134 135 … 172
Go toTop